PDIA3 mutations have implications in lung cancer via abnormal immunosurveillance [45], while FOXP3 acts as a co‐activator in NSCLC, promoting Wnt/β‐catenin signaling, epithelial‐mesenchymal transition, and metastasis [46]. The gene discussed is FOXP3; the disease is lung cancer.